Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer

Background: Preclinical evidence suggests synergy between docetaxel and irinotecan, two drugs active in esophagogastric cancer. We previously demonstrated the safety of docetaxel 35 mg/m(2) and irinotecan 50 mg/m(2) given on days 1 and 8 of a 21-day schedule. Materials and methods: Patients who had...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Burtness, B., Gibson, M., Egleston, B., Mehra, R., Thomas, L., Sipples, R., Quintanilla, M., Lacy, J., Watkins, S., Murren, J. R., Forastiere, A. A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2009
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2699385/
https://ncbi.nlm.nih.gov/pubmed/19429872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn787
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak